Regeneron Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 03/29/2024
Regeneron Pharmaceuticals Stock Forecast and Price Target
The average target price for Regeneron Pharmaceuticals's stock set by eight renowned analysts in recent months is $1050.00, representing a potential upside of approximately 8.87% from its last closing price if met by 2025. This estimation is based on a high estimate of $1184.00 and a low estimate of $710.00. If you want to invest in REGN stock, you might also want to take a look at how its competitors are doing.
8.87% Upside
Regeneron Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Regeneron Pharmaceuticals's Price has seen a drop from $490.30 to $0.00 – a 100.00% decrease. Analysts predict that Regeneron Pharmaceuticals's Fair Value will increase in the upcoming year, reaching $743.01. This would represent an increase of 100.00%. Over the next seven years, experts predict that Regeneron Pharmaceuticals's Fair Value will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ABBV Stock Forecast | AbbVie | Outperform |
9
|
$179.63 | Buy/Sell | $178.42 | 0.21% |
CMCSA Stock Forecast | Comcast Corp | Outperform |
10
|
$43.54 | Buy/Sell | $50.29 | 16.49% |
VZ Stock Forecast | Verizon Communications | Outperform |
6
|
$40.13 | Buy/Sell | $45.10 | 14.00% |
PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.37 | Buy/Sell | $32.87 | 10.82% |
AMGN Stock Forecast | Amgen | Outperform |
4
|
$275.36 | Buy/Sell | $303.65 | 14.40% |
Regeneron Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Regeneron Pharmaceuticals's Revenue has seen an increase, rising from $8.31B to $13.12B. This represents a growth of 57.84%. According to 16 major analysts, Regeneron Pharmaceuticals's Revenue will fall by 2.04% in the next year, reaching $12.85B. Professionals believe that By 2030, Regeneron Pharmaceuticals's Revenue will fall to $11.25B– a 14.21% decrease from its current value.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$54.36 | Buy/Sell | $58.15 | 1.18% |
GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$75.32 | Buy/Sell | $87.82 | 10.20% |
4519 Stock Forecast | Chugai Pharmaceutical | Outperform |
6
|
¥6.51k | Buy/Sell | ¥4.92k | -5.57% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
2914 Stock Forecast | Japan Tobacco | Outperform |
6
|
¥3.82k | Buy/Sell | ¥3.25k | 1.99% |
4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.31k | Buy/Sell | ¥4.74k | 6.63% |
ALC Stock Forecast | Alcon | Outperform |
8
|
CHF77.20 | Buy/Sell | CHF90.64 | 24.62% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BIIB Stock Forecast | Biogen | Outperform |
10
|
$230.07 | Buy/Sell | $299.62 | 29.09% |
CE Stock Forecast | Celanese | Hold |
13
|
$157.43 | Buy/Sell | $148.23 | 1.63% |
BGNE Stock Forecast | BeiGene | Buy |
6
|
$164.53 | Buy/Sell | $285.19 | 67.14% |
Regeneron Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
Regeneron Pharmaceuticals's EBITDA has grown in the last three years, jumping from $3.53B to $4.65B – an increase of 31.82%. In the next year, analysts predict that EBITDA will reach $7.12B – an increase of 52.92%. For the next seven years, the forecast is for EBITDA to grow by 28.17%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
INCY Stock Forecast | Incyte | Outperform |
9
|
$60.79 | Buy/Sell | $77.05 | 26.99% |
UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$249.51 | Buy/Sell | $284.08 | 19.63% |
JAZZ Stock Forecast | Jazz Pharmaceuticals | Outperform |
14
|
$116.63 | Buy/Sell | $188.32 | 59.52% |
Regeneron Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Regeneron Pharmaceuticals's EBIT has increased by 28.48%, going from $3.29B to $4.23B. In the next year, analysts are expecting an increase in EBIT, predicting it will reach $5.27B – an increase of 24.39%. The Regeneron Pharmaceuticals forecast is for EBIT to reach $4.43B or grow by 4.55%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$43.26 | Buy/Sell | $55.60 | 41.01% |
EXEL Stock Forecast | Exelixis | Outperform |
16
|
$22.46 | Buy/Sell | $26.44 | 20.21% |
SPIE Stock Forecast | SPIE | Outperform |
18
|
33.82€ | Buy/Sell | 32.33€ | 10.88% |
Regeneron Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Regeneron Pharmaceuticals's EPS has seen a drop from $31.47 to $0.00 – a 100.00% decrease. Analysts predict that Regeneron Pharmaceuticals's EPS will increase in the upcoming year, reaching $47.69. This would represent an increase of 100.00%. Over the next seven years, experts predict that Regeneron Pharmaceuticals's EPS will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BHC Stock Forecast | Bausch Health Companies | Hold |
15
|
$9.12 | Buy/Sell | $9.50 | -1.32% |
MRUS Stock Forecast | Merus N.V. | Buy |
6
|
$47.72 | Buy/Sell | $43.70 | 20.49% |
GLPG Stock Forecast | Galapagos NV | Hold |
6
|
31.94€ | Buy/Sell | 39.85€ | 13.49% |